Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 14/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901526 | 0.81 | TRPA1 (0.54) | DRD1TRPA1HTR2AHTR2C | |
| SCHEMBL7814847 | 0.76 | TRPA1 (0.50) | DRD1TRPA1SSTR4 | |
| SCHEMBL31091535 | 0.76 | MAOB (0.50) | DRD1TRPA1HPGD | |
| SCHEMBL20171944 | 0.75 | TRPA1 (0.49) | DRD1TRPA1HPGDSMN1; SMN2 | |
| SCHEMBL8371407 | 0.73 | HTR2C (0.42) | DRD1TRPA1SSTR4HTR2AHTR2C | |
| SCHEMBL21999457 | 0.71 | DRD1 (0.58) | DRD1TRPA1 | |
| SCHEMBL11628396 | 0.71 | ADRB2 (0.48) | SMN1; SMN2HTR2AHTR2CHTR2B | |
| SCHEMBL827370 | 0.70 | KCNA3 (0.59) | DRD1TRPA1HPGDHTR2AHTR2C | |
| SCHEMBL3797772 | 0.70 | BRD4 (0.46) | TRPA1 | |
| SCHEMBL2757287 | 0.70 | HTR2C (0.47) | DRD1TRPA1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804864-B1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2804864-B1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9643974-B2 | Amino-substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-05-09 | — | — | US | disclosed |
| US-9643974-B2 | Amino-substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-05-09 | — | — | US | disclosed |
| US-9643974-B2 | Amino-substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-05-09 | — | — | US | disclosed |
| EP-2714692-B1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20140364435-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-11 | — | — | US | disclosed |
| EP-2804864-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| WO-2013087581-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-8343477-B2 | Viricides; serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2012163942-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | DRD1 3272/4885TRPA1 4837/4885HPGD 3422/4885 |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | TERT, VIP, YWHAZ | DRD1 428/4885TRPA1 3751/4885HPGD 3271/4885 |
| US-20140364435-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | CCND2, CCND1, VEGFA | DRD1 894/4885TRPA1 4706/4885HPGD 208/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | DRD1 3272/4885TRPA1 4837/4885HPGD 3422/4885 |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | CCND2, CCND1, VEGFA | DRD1 1330/4885TRPA1 4570/4885HPGD 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.